NY-DAVIS-POLK
17.1.2023 16:34:38 CET | Business Wire | Press release
Davis Polk today announced that the firm is launching a European antitrust practice in Brussels. The practice will be led by Jürgen Schindler and Frances Dethmers.
“The European Commission is a critical antitrust authority. We are excited to be able to offer our clients sophisticated antitrust capabilities with respect to matters under EU law,” said Neil Barr, Davis Polk’s Managing Partner. “We are thrilled to welcome Jürgen and Frances to Davis Polk.”
The firm’s office in Brussels will open in 2023.
Mr. Schindler and Ms. Dethmers join the firm from Allen & Overy, where both served as partners and Mr. Schindler as co-head of the global competition and antitrust group. Mr. Schindler has extensive experience advising clients on complex international, EU and German merger control, cartel and abuse of dominance cases. His practice encompasses a broad range of sectors, including energy, finance, technology, transport (shipping and airlines), raw materials, chemicals, pharmaceuticals, and consumer and industrial products. In addition, Mr. Schindler litigates before the European courts in Luxembourg.
Mr. Schindler’s practice has extensive geographic coverage; he has advised clients in Europe, the United States, Latin America, Asia and the Middle East. He is admitted to practice in Germany, Belgium and New York. He will join Davis Polk as a partner.
He is a Non-Governmental Adviser to the European Commission and to the German Competition Authority at the International Competition Network (ICN), which includes around 140 competition authorities worldwide, and he regularly contributes to the ICN’s cartel and merger working groups. In addition, he is a long-time editorial board member of the ABA’s Antitrust Magazine Online.
Ms. Dethmers’ practice focuses on international, EU and Dutch competition law. She is an economist and a qualified lawyer. She has extensive experience advising clients from a wide range of industries (in particular, pharmaceuticals, health and life sciences, consumer and industrial products, chemicals and packaging) on highly complex merger control procedures, as well as on cartel investigations, abuse of dominance investigations, intellectual property issues and licensing and distribution agreements. Prior to working in private practice, she worked at the Dutch Competition Authority and the European Commission. Her background as an economist gives her unique insight into the economic concepts and analytical tools at the heart of competition law. She is admitted to practice in the Netherlands. She will join Davis Polk as Special Adviser – EU Antitrust.
“Jürgen and Frances are exceptional lawyers with an outstanding reputation in Brussels, and we are thrilled to have them on board to help us launch our EU antitrust practice,” said Art Burke, head of Davis Polk’s Antitrust & Competition practice. “Their significant experience across merger control matters, cartels and antitrust litigation will benefit our clients greatly and will further solidify our position as a leading global antitrust firm.”
Davis Polk is recognized as a preeminent firm in antitrust and competition law, including with top-tier rankings from publications such as Global Competition Review, Benchmark Litigation and Chambers USA. Clients rely on Davis Polk’s deep experience across the full spectrum of antitrust and competition matters. The firm steers clients through sensitive antitrust investigations and high-stakes litigation, including class actions and government enforcement actions. Davis Polk also serves in a lead role for large defense groups, including in cases alleging cartel behavior in numerous industries and financial markets. Having addressed and resolved antitrust issues presented by thousands of transactions across all economic sectors, the firm is widely recognized in particular for its work on cross-border combinations and routinely acts as coordinating counsel for international merger control review for complex transactions.
Mr. Schindler said, “Frances and I are very excited to be joining Davis Polk, a firm we have long held in high esteem. We have been struck by the strong culture that permeates throughout the firm, and we very much look forward to working with this fantastic team and helping the firm to execute on this strategic expansion of its global antitrust capabilities. We are very grateful for our time as partners at Allen & Overy.”
Ranked as a leading EU competition lawyer by Chambers Europe, Mr. Schindler in 1999 graduated from the University of Hamburg and earned an LLM in European Law from the College of Europe in Bruges. In 2007, he earned an LLM from Georgetown University Law Center focusing on U.S. antitrust law and economics. Ms. Dethmers earned a master’s degree in economics in 1998 and a master’s degree in law in 2001, both from the University of Amsterdam.
About Davis Polk.
Davis Polk & Wardwell LLP (including its associated entities) is an elite global law firm with world-class practices across the board. Clients know they can rely on us for their most challenging legal and business matters. From offices in the world’s key financial centers and political capitals, our more than 1,000 lawyers collaborate seamlessly to deliver exceptional service, sophisticated advice and creative, practical solutions. Visit davispolk.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005803/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
